Asenapine increases nitric oxide release and protects porcine coronary artery endothelial cells against peroxidation

Vascular Pharmacology

Volumn 60, Issue 3, 2014, Pages 127-141

  Grossini, Elena ^a   Gramaglia, Carla ^a   Farruggio, Serena ^a   Bellofatto, Kevin ^a   Anchisi, Chiara ^a   Mary, David ^a   Vacca, Giovanni ^a   Zeppegno, Patrizia ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Antipsychotic drugs; Apoptosis; Cell survival; Endothelium; Nitric oxide

Indexed keywords

ANTIOXIDANT; ASENAPINE; BETA 2 ADRENERGIC RECEPTOR; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FORSKOLIN; GLUTATHIONE; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; PHOSPHOLIPASE C; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; TETRAHYDROBIOPTERIN; CARDIOTONIC AGENT; FUSED HETEROCYCLIC RINGS;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTERY ENDOTHELIUM; ARTICLE; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME REGULATION; INTRACELLULAR SIGNALING; LIPID PEROXIDATION; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SWINE; WESTERN BLOTTING; ANIMAL; CELL CULTURE; CORONARY BLOOD VESSEL; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; SECRETION (PROCESS);

ANIMALS; CARDIOTONIC AGENTS; CELLS, CULTURED; CORONARY VESSELS; ENDOTHELIAL CELLS; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; LIPID PEROXIDATION; NITRIC OXIDE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SWINE;

EID: 84895517393     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2014.01.008     Document Type: Article

References (69)

1. Al Zubair K., Bexis S., Docherty J.R. Relaxations to β-adrenoceptor subtype selective agonists in wild-type and NOS-3-KO mouse mesenteric arteries. Eur J Pharmacol 2008, 587:216-223.
2. Arney R.M., Freedland K.E., Miller G.E., Jaffe A.S. Depression as a risk factor for cardiac mortality and morbidity: a review of potential mechanisms. J Psychosom Res 2002, 53:897-902.
3. Bär K., Koschke M., Boettger M.K., Berger S., Kabisch A., Sauer H., et al. Acute psychosis leads to increased QT variability in patients suffering from schizophrenia. Schizophr Res 2007, 95:115-123.
4. Birder L.A., Nealen M.L., Kiss S., de Groat W.C., Caterina M.J., Wang E., et al. Beta-adrenoceptor agonists stimulate endothelial nitric oxide synthase in rat urinary bladder urothelial cells. J Neurosci 2002, 22:8063-8070.
5. Bresee L.C., Majumdar S.R., Patten S.B., Johnson J.A. Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophr Res 2010, 117:75-82.
6. Brown S., Kim M., Mitchell C., Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry 2010, 196:116-121.
7. Caimmi P.P., Molinari C., Uberti F., Micalizzi E., Valente G., Mary D.A., et al. Intracoronary levosimendan prevents myocardial ischemic damages and activates survival signaling through ATP-sensitive potassium channel and nitric oxide. Eur J Cardiothorac Surg 2011, 39:e59-e67.
8. Cappellano G., Uberti F., Caimmi P.P., Pietronave S., Mary D.A., Dianzani C., et al. Different expression and function of the endocannabinoid system in human epicardial adipose tissue in relation to heart disease. Can J Cardiol 2013, 29:499-509.
9. Chrapko W., Jurasz P., Radomski M.W., Archer S.L., Newman S.C., Baker G., Lara N., Le Mellédo J.M. Alteration of decreased plasma NO metabolites and platelet NO synthase activity by paroxetine in depressed patients. Neuropsychopharmacology 2006, 31(6):1286-1293.
10. Ciccarelli M., Cipolletta E., Santulli G., Campanile A., Pumiglia K., Cervero P., et al. Endothelial beta2 adrenergic signaling to AKT: role of Gi and SRC. Cell Signal 2007, 19:1949-1955.
11. Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract 2009, 63:1762-1784.
12. Cohen H., Benjamin J., Geva A.B., Matar M.A., Kaplan Z., Kotler M. Autonomic dysregulation in panic disorder and in post-traumatic stress disorder: application of power spectrum analysis of heart rate variability at rest and in response to recollection of trauma or panic attacks. Psychiatry Res 2000, 96:1-13.
13. Cook S. Coronary artery disease, nitric oxide and oxidative stress: the "Yin-Yang" effect-a Chinese concept for a worldwide pandemic. Swiss Med Wkly 2006, 13:103-113.
14. Cook S., Scherrer U. Insulin resistance, a new target for nitric oxide-delivery drugs. Fundam Clin Pharmacol 2002, 16:441-453.
15. Crabtree M.J., Brixey R., Batchelor H., Hale A.B., Channon K.M. Integrated redox sensor and effector functions for tetrahydrobiopterin- and glutathionylation-dependent endothelial nitric-oxide synthase uncoupling. J Biol Chem 2013, 288:561-569.
16. de Belder A., Radomski M., Hancock V., Brown A., Moncada S., Martin J. Megakaryocytes from patients with coronary atherosclerosis express the inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol 1995, 15:637-641.
17. De Hert M., Detraux J., van Winkel R., Yu W., Correll C.U. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2011, 8:114-126.
18. Dusting G.J., Macdonald P.S. Endogenous nitric oxide in cardiovascular disease and transplantation. Ann Med 1995, 27:395-406.
19. Ellingrod V.L., Taylor S.F., Brook R.D., Evans S.J., Zöllner S.K., Grove T.B., et al. Dietary, lifestyle and pharmacogenetic factors associated with arteriole endothelial-dependent vasodilatation in schizophrenia patients treated with atypical antipsychotics (AAPs). Schizophr Res 2011, 130:20-26.
20. Faulx M.D., Wright A.T., Hoit B.D. Detection of endothelial dysfunction with brachial artery ultrasound scanning. Am Heart J 2003, 145:943-951.
21. Ferro A., Queen L.R., Priest R.M., Xu B., Ritter J.M., Poston L., et al. Activation of nitric oxide synthase by beta 2-adrenoceptors in human umbilical vein endothelium in vitro. Br J Pharmacol 1999, 126:1872-1880.
22. Fiedorowicz J.G., Coryell W.H., Rice J.P., Warren L.L., Haynes W.G. Vasculopathy related to manic/hypomanic symptom burden and first-generation antipsychotics in a sub-sample from the collaborative depression study. Psychother Psychosom 2012, 81:235-243.
23. Grossini E., Caimmi P., Molinari C., Uberti F., Mary D., Vacca G. CCK receptors-related signaling involved in nitric oxide production caused by gastrin 17 in porcine coronary endothelial cells. Mol Cell Endocrinol 2012, 350:20-30.
24. Grossini E., Molinari C., Caimmi P.P., Uberti F., Vacca G. Levosimendan induces NO production through p38 MAPK, ERK and Akt in porcine coronary endothelial cells: role for mitochondrial K(ATP) channel. Br J Pharmacol 2009, 156:250-261.
25. Grossini E., Molinari C., Sigaudo L., Biella M., Mary D.A., Vacca G. Calcium handling in porcine coronary endothelial cells by gastrin-17. J Mol Endocrinol 2013, 50:243-253.
26. Grossini E., Molinari C., Mary D.A., Uberti F., Ribichini F., Caimmi P.P., et al. Urocortin II induces nitric oxide production through cAMP and Ca2+ related pathways in endothelial cells. Cell Physiol Biochem 2009, 23:87-96.
27. Grossini E., Molinari C., Mary D.A., Uberti F., Caimmi P.P., Vacca G. Intracoronary intermedin 1-47 augments cardiac perfusion and function in anesthetized pigs: role of calcitonin receptors and beta-adrenoreceptor-mediated nitric oxide release. J Appl Physiol 2009, 107:1037-1050.
28. Hoffmann A., Gloe T., Pohl U., Zahler S. Nitric oxide enhances de novo formation of endothelial gap junctions. Cardiovasc Res 2003, 60:421-430.
29. Iaccarino G., Cipolletta E., Fiorillo A., Annecchiarico M., Ciccarelli M., Cimini V., et al. Beta(2)-adrenergic receptor gene delivery to the endothelium corrects impaired adrenergic vasorelaxation in hypertension. Circulation 2002, 106:349-355.
30. Ignarro L.J. Endothelium-derived nitric oxide: actions and properties. FASEB J 1989, 3:31-36.
31. Inserte J., Hernando V., Vilardosa Ú., Abad E., Poncelas-Nozal M., Garcia-Dorado D. Activation of cGMP/protein kinase G pathway in postconditioned myocardium depends on reduced oxidative stress and preserved endothelial nitric oxide synthase coupling. J Am Heart Assoc 2013, 2(1). e005975. http://dx.doi.org/10.1161/JAHA.112.005975.
32. Javadov S., Karmazyn M. Mitochondrial permeability transition pore opening as an endpoint to initiate cell death and as a putative target for cardioprotection. Cell Physiol Biochem 2007, 20:1-22.
33. Johansson L., Sohn D., Thorberg S.O., Jackson D.M., Kelder D., Larsson L.G., et al. The pharmacological characterization of a novel selective 5-hydroxytryptamine1A receptor antagonist, NAD-299. J Pharmacol Exp Ther 1997, 283:216-225.
34. Kilbourn R.G., Traber D.L., Szabo C. Nitric oxide and shock. Dis Mon 1997, 43:277-348.
35. Laursen T.M., Munk-Olsen T., Vestergaard M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry 2012, 25:83-88.
36. Lavoie K.L., Pelletier R., Arsenault A., Dupuis J., Bacon S.L. Association between clinical depression and endothelial function measured by forearm hyperemic reactivity. Psychosom Med 2010, 72:20-26.
37. Liaudet L., Soriano F.G., Szabo C. Biology of nitric oxide signaling. Crit Care Med 2000, 28:N37-N52.
38. Luo S.S., Sugimoto K., Fujii S., Takemasa T., Fu S.B., Yamashita K. Role of heat shock protein 70 in induction of stress fiber formation in rat arterial endothelial cells in response to stretch stress. Acta Histochem Cytochem 2007, 40:9-17.
39. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005, 80:19-32.
40. Okouchi M., Okayama N., Aw T.Y. Preservation of cellular glutathione status and mitochondrial membrane potential by N-acetylcysteine and insulin sensitizers prevent carbonyl stress-induced human brain endothelial cell apoptosis. Curr Neurovasc Res 2009, 6:267-278.
41. Ormel J., de Jonge P. Unipolar depression and the progression of coronary artery disease: toward an integrative model. Psychother Psychosom 2011, 80:264-274.
42. Osborn D.P., Baio G., Walters K., Petersen I., Limburg H., Raine R., et al. Inequalities in the provision of cardiovascular screening to people with severe mental illnesses in primary care: cohort study in the United Kingdom THIN Primary Care Database 2000-2007. Schizophr Res 2011, 129:104-110.
43. Padmasekar M., Nandigama R., Wartenberg M., Schluter K.D., Sauer H. The acute phase protein alpha2-macroglobulin induces rat ventricular cardiomyocyte hypertrophy via ERK1,2 and PI3-kinase/Akt pathways. Cardiovasc Res 2007, 75:118-128.
44. Parenti A., Filippi S., Amerini S., Granger H.J., Fazzini A., Ledda F. Inositol phosphate metabolism and nitric-oxide synthase activity in endothelial cells are involved in the vasorelaxant activity of nebivolol. J Pharmacol Exp Ther 2000, 292:698-703.
45. Pizzi C., Manzoli L., Mancini S., Costa G.M. Analysis of potential predictors of depression among coronary heart disease risk factors including heart rate variability, markers of inflammation, and endothelial function. Eur Heart J 2008, 29:1110-1117.
46. Polte T., Schröder H. Cyclic AMP mediates endothelial protection by nitric oxide. Biochem Biophys Res Commun 1998, 20:460-465.
47. Rajagopalan S., Brook R., Rubenfire M., Pitt E., Young E., Pitt B. Abnormal brachial artery flow-mediated vasodilation in young adults with major depression. Am J Cardiol 2001, 88:196-198.
48. Raymond J.R., Mukhin Y.V., Gettys T.W., Garnovskaya M.N. The recombinant 5-HT1A receptor: G protein coupling and signalling pathways. Br J Pharmacol 1999, 127:1751-1764.
49. Razavi H.M., Hamilton J.A., Feng Q. Modulation of apoptosis by nitric oxide: implications in myocardial ischemia and heart failure. Pharmacol Ther 2005, 106:147-162.
50. Reynolds G.P. Receptor mechanisms of antipsychotic drug action in bipolar disorder-focus on asenapine. Ther Adv Psychopharmacol 2011, 1:197-204.
51. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836-843.
52. Rozanski A., Blumenthal J.A., Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 1999, 99:2192-2217.
53. Rybakowski J.K., Wykretowicz A., Heymann-Szlachcinska A., Wysocki H. Impairment of endothelial function in unipolar and bipolar depression. Biol Psychiatry 2006, 60:889-891.
54. Saadeddin S.M., Habbab M.A., Ferns G.A. Markers of inflammation and coronary artery disease. Med Sci Monit 2002, 8:RA5-RA12.
55. Samalin L., Charpeaud T., Llorca P.M. Asenapine in bipolar I disorder: evidence and place in patient management. Ther Adv Chronic Dis 2013, 4(1):5-14. http://dx.doi.org/10.1177/2040622312468933.
56. Shah S.U., White A., White S., Littler W.A. Heart and mind: (1) relationship between cardiovascular and psychiatric conditions. Postgrad Med J 2004, 80:683-689.
57. Shen B.J., Avivi Y.E., Todaro J.F., Spiro A., Laurenceau J.P., Ward K.D., et al. Anxiety characteristics independently and prospectively predict myocardial infarction in men: the unique contribution of anxiety among psychologic factors. J Am Coll Cardiol 2008, 51:113-119.
58. Shimokawa H. Primary endothelial dysfunction: atherosclerosis. J Mol Cell Cardiol 1999, 31:23-37.
59. Skala J.A., Freedland K.E., Carney R.M. Coronary heart disease and depression: a review of recent mechanistic research. Can J Psychiatry 2006, 51:738-745.
60. Sowden G.L., Huffman J.C. The impact of mental illness on cardiac outcomes: a review for the cardiologist. Int J Cardiol 2009, 132:30-37.
61. Stoner S.C., Pace H.A. Asenapine: a clinical review of a second-generation antipsychotic. Clin Ther 2012, 34:1023-1040.
62. Su Y., Qadri S.M., Wu L., Liu L. Methylglyoxal modulates endothelial nitric oxide synthase-associated functions in EA.hy926 endothelial cells. Cardiovasc Diabetol 2013, 12:134.
63. Sullivan J.A., Grummer M.A., Yi F.X., Bird I.M. Pregnancy-enhanced endothelial nitric oxide synthase (eNOS) activation in uterine artery endothelial cells shows altered sensitivity to Ca2+, U0126, and wortmannin but not LY294002-evidence that pregnancy adaptation of eNOS activation occurs at multiple levels of cell signaling. Endocrinology 2006, 147:2442-2457.
64. Uberti F., Caimmi P.P., Molinari C., Mary D., Vacca G., Grossini E. Levosimendan modulates programmed forms of cell death through K(ATP) channels and nitric oxide. J Cardiovasc Pharmacol 2011, 57:246-258.
65. Wen Y.D., Wang H., Kho S.H., Rinkiko S., Sheng X., Shen H.M., et al. Hydrogen sulfide protects HUVECs against hydrogen peroxide induced mitochondrial dysfunction and oxidative stress. PLoS One 2013, 8(2). e53147. http://dx.doi.org/10.1371/journal.pone.0053147.
66. Zhang X.Y., Zhou D.F., Shen Y.C., Zhang P.Y., Zhang W.F., Liang J., et al. Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia. Neuropharmacology 2012, 62:1928-1934.
67. Zuidersma M., Thombs B.D., de Jonge P. Onset and recurrence of depression as predictors of cardiovascular prognosis in depressed acute coronary syndrome patients: a systematic review. Psychother Psychosom 2011, 80:227-237.
68. Green D.R., Reed J.C. Mitochondria and apoptosis. Science 1998 Aug 28, 281(5381):1309-1312.
69. Russell J.W., Golovoy D., Vincent A.M., Mahendru P., Olzmann J.A., Mentzer A., Feldman E.L. High glucose-induced oxidative stress and mitochondrial dysfunction in neurons. FASEB J 2002 Nov, 16(13):1738-1748.